CD40 and neoplasm: To determine how treatment with anti-CD40 mAb, sunitinib or the combination affects the prevalence of cytotoxic T-cells within the tumor tissue, we performed immunostaining for the cytotoxic T-cell marker CD8 in B16.F10 and T241 tumor sections.